紅山生物製藥有限公司(納斯達克代碼：RDHL)的空頭股數價格大幅下降

RedHill Biopharma Ltd. (NASDAQ:RDHL – Get Rating) saw a significant drop in short interest in the month of June. As of June 15th, there was short interest totalling 1,270,000 shares, a drop of 17.0% from the May 31st total of 1,530,000 shares. Based on an average daily volume of 1,840,000 shares, the short-interest ratio is presently 0.7 days.

Separately, StockNews.com initiated coverage on shares of RedHill Biopharma in a report on Thursday, March 31st. They issued a "hold" rating on the stock.

Get

RedHill Biopharma

alerts:

RedHill Biopharma stock opened at $0.92 on Thursday. The company has a market cap of $48.21 million, a P/E ratio of -0.49 and a beta of 1.95. RedHill Biopharma has a 1-year low of $0.62 and a 1-year high of $11.18. The company has a fifty day simple moving average of $1.03 and a 200 day simple moving average of $1.89. The company has a current ratio of 0.98, a quick ratio of 0.79 and a debt-to-equity ratio of 9.42.

RedHill Biopharma (NASDAQ:RDHL – Get Rating) last announced its quarterly earnings data on Thursday, June 23rd. The biotechnology company reported ($0.30) EPS for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.07). RedHill Biopharma had a negative net margin of 110.31% and a negative return on equity of 822.29%. During the same quarter in the prior year, the company posted ($0.53) earnings per share. On average, equities research analysts forecast that RedHill Biopharma will post -0.95 EPS for the current year.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. Disciplined Growth Investors Inc. MN raised its stake in RedHill Biopharma by 0.7% in the 1st quarter. Disciplined Growth Investors Inc. MN now owns 1,950,002 shares of the biotechnology company's stock worth $4,914,000 after purchasing an additional 14,413 shares in the last quarter. ARK Investment Management LLC acquired a new stake in RedHill Biopharma in the 1st quarter worth about $2,172,000. Gagnon Securities LLC raised its stake in RedHill Biopharma by 15.4% in the 1st quarter. Gagnon Securities LLC now owns 367,346 shares of the biotechnology company's stock worth $926,000 after purchasing an additional 49,023 shares in the last quarter. BlackRock Inc. raised its stake in RedHill Biopharma by 18.6% in the 1st quarter. BlackRock Inc. now owns 357,493 shares of the biotechnology company's stock worth $901,000 after purchasing an additional 56,178 shares in the last quarter. Finally, GSA Capital Partners LLP raised its stake in RedHill Biopharma by 108.4% in the 4th quarter. GSA Capital Partners LLP now owns 218,338 shares of the biotechnology company's stock worth $563,000 after purchasing an additional 113,584 shares in the last quarter. Institutional investors own 11.08% of the company's stock.

About RedHill Biopharma (Get Rating)

RedHill Biopharma Ltd., a specialty biopharmaceutical company, primarily focuses on gastrointestinal and infectious diseases. The company promotes gastrointestinal drugs, including Movantik for opioid-induced constipation in adults with chronic non-cancer pain; Talicia for the treatment of Helicobacter pylori infection in adults; and Aemcolo for the treatment of travelers' diarrhea in adults.

Further Reading

• Get a free copy of the StockNews.com research report on RedHill Biopharma (RDHL)
• Recession Resistant Grocery Outlet Holding Corp Quietly Sets New High
• It's Not Too Late For These Undervalued Energy Stocks
• Three Cheap Stocks That Just Got Upgraded
• 3 Home Improvement Stocks That Can Renovate Your Portfolio
• Looking to Dump These 3 Possible Delisted Chinese Stocks? Let's Take a Look.

Receive News & Ratings for RedHill Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RedHill Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.